TECENTRIQ is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Atezolizumab.
| Product ID | 50242-917_0db9ee06-7a81-45f8-862b-b84180b9db13 | 
| NDC | 50242-917 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | TECENTRIQ | 
| Generic Name | Atezolizumab | 
| Dosage Form | Injection, Solution | 
| Route of Administration | INTRAVENOUS | 
| Marketing Start Date | 2016-05-18 | 
| Marketing Category | BLA / BLA | 
| Application Number | BLA761034 | 
| Labeler Name | Genentech, Inc. | 
| Substance Name | ATEZOLIZUMAB | 
| Active Ingredient Strength | 1200 mg/20mL | 
| Pharm Classes | Programmed Death Receptor-1 Blocking Antibody [EPC],Antibodies, Monoclonal, Humanized [CS],Antibodies, Monoclonal [CS],Antibodies [CS],Programmed Death Receptor-1-directed Antibody Interactions [MoA] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2022-12-31 | 
| Marketing Start Date | 2016-05-18 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Marketing Category | BLA | 
| Application Number | BLA761034 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Marketing Start Date | 2016-08-11 | 
| Marketing Category | BLA | 
| Application Number | BLA761034 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Billing Unit | ML | 
| Marketing Start Date | 2016-05-18 | 
| Ingredient | Strength | 
|---|---|
| ATEZOLIZUMAB | 1200 mg/20mL | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 50242-917 | TECENTRIQ | atezolizumab | 
| 50242-918 | TECENTRIQ | atezolizumab | 
Mark Image Registration | Serial  | Company  Trademark Application Date  | 
|---|---|
![]() TECENTRIQ  86441478  5027722 Live/Registered  | 
        GENENTECH, INC.  2014-10-31  |